Certolizumab pegol reduces symptoms in patients with moderately to severely active Crohn's disease - Commentary

Edward V. Loftus

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Certolizumab pegol reduces symptoms in patients with moderately to severely active Crohn's disease - Commentary'. Together they form a unique fingerprint.